San Diego-based mostly Viking Therapeutics marked itself as a significant competitor from the weight loss drug industry in February right after revealing promising data from the mid-stage demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when given for a weekly injection and in March the company unv